Rapid Diagnosis of Human Immunodeficiency Virus Infection Using OraQuick(r) Advance Rapid HIV-1/2 Antibody Test / 감염과화학요법

BACKGROUND: From medical care perspective regarding HIV, early detection of HIV is critical in effectively managing its sequelae. People who are aware of the fact that they are infected with HIV significantly reduce high risk behaviors, thus limiting transmission to others compared to individuals who are unaware of their HIV serostatus. MATERIALS AND METHODS: HIV rapid test validation study was conducted at Asan medical center using OraQuick Advance Rapid HIV-1/2 Antibody Test which uses oral fluid specimens for the diagnosis of HIV infection. A total of 57 subjects were tested; 53 individuals were confirmed to have HIV infection by the Western blot analysis and 4 individuals were negative for HIV. RESULTS: The oral fluid specimens from 52 of 53 infected individuals showed positive reaction to the OraQuick Advance Rapid HIV-1/2 Antibody Test. The test results were negative for the 4 subjects who were negative for HIV. OraQuick Advance Rapid HIV-1/2 Antibody Test's sensitivity was 98.1%, specificity was 100%, positive predictive value was 100%, and negative predictive value was 80%. CONCLUSION: The recently approved OraQuick Advance Rapid HIV-1/2 Antibody Test has the ability to detect HIV antibodies comparable to that of confirmatory tests such as Western blot analysis.

Rapid Diagnosis of Human Immunodeficiency Virus Infection Using OraQuick(r) Advance Rapid HIV-1/2 Antibody Test / 감염과화학요법

BACKGROUND: From medical care perspective regarding HIV, early detection of HIV is critical in effectively managing its sequelae. People who are aware of the fact that they are infected with HIV significantly reduce high risk behaviors, thus limiting transmission to others compared to individuals who are unaware of their HIV serostatus. MATERIALS AND METHODS: HIV rapid test validation study was conducted at Asan medical center using OraQuick Advance Rapid HIV-1/2 Antibody Test which uses oral fluid specimens for the diagnosis of HIV infection. A total of 57 subjects were tested; 53 individuals were confirmed to have HIV infection by the Western blot analysis and 4 individuals were negative for HIV. RESULTS: The oral fluid specimens from 52 of 53 infected individuals showed positive reaction to the OraQuick Advance Rapid HIV-1/2 Antibody Test. The test results were negative for the 4 subjects who were negative for HIV. OraQuick Advance Rapid HIV-1/2 Antibody Test's sensitivity was 98.1%, specificity was 100%, positive predictive value was 100%, and negative predictive value was 80%. CONCLUSION: The recently approved OraQuick Advance Rapid HIV-1/2 Antibody Test has the ability to detect HIV antibodies comparable to that of confirmatory tests such as Western blot analysis.

Evaluation of OraQuick Advance Rapid HIV-1/2 Antibody Test as a Screening Test for HIV Infection / 대한임상미생물학회지

BACKGROUND: For the diagnosis of HIV infection, enzyme immunoassay (EIA) or chemiluminescence immunoassay (CLIA) is commonly used as a screening test. Although these methods have a high sensitivity and low cost, their high false positive rate can cause confusion in the patients and clinicians until a more specific test is done. OraQuick Advance Rapid HIV-1/2 Antibody Test (OraQuick) (OraSure Technologies, USA) is a rapid test that can detect HIV-1/2 antibodies in 20 minutes. It uses oral fluid, whole blood or serum sample. In this study, we evaluated the usefulness of the OraQuick as a screening and point-of-care test for HIV infection. METHODS: From Jan 2007 to Dec 2008, 45,276 samples referred to our laboratory were tested by CLIA method using the ADVIA Centaur (Bayer Healthcare LTD., USA) for HIV-1/2 antibody detection. Among them, 74 positive and 50 negative samples were tested by the Western immunoblot assay (WIB) and OraQuick test as a case-control study. Also, oral fluids from 30 HIV patients and 48 healthy persons were tested by OraQuick test. RESULTS: The sensitivity and specificity of OraQuick test (using serum samples) were 100% and 98.8% (95% confidence interval 96.9~100%), respectively. OraQuick tests (using oral fluid samples) were all positive for HIV patients but all negative for healthy persons. CONCLUSIONS: This study suggests that OraQuick can be used successfully as a rapid test for the early detection of HIV-1/2 antibody in patients visiting emergency departments and for the prevention of HIV infection in the health care providers.

Evaluation of a Screening Test kit of Simultaneous p24 Antigen and Anti-HIV1/2 Detection in Diagnostic Aspect / 대한임상병리학회지

BACKGROUND: Human immunodeficiency virus(HIV) is the causative agent of acquired immune deficiency syndrome(AIDS). Current diagnosis of HIV infection relies on the detection of anti-HIV antibodies by ELISA. Recently, simultaneous detection kit of p24 antigenemia and anti-HIV1/anti-HIV2 antibodies were developed. The aim of this study was to evaluate the diagnostic kit of simultaneous detection with p24 antigen and anti-HIV1/2 in diagnostic aspect. METHODS: Eight hundred and four sera which were obtained between July 1999 and August 1999 and 110 sera from 54 patients diagnosed as HIV infection were included. One lot of panels composed of consecutive sera obtained from known HIV-infected patients was included. The detection of anti-HIV1/2 antibodies was done by Genedia HIV1/2 ELISA 3.0 kit(Greencross, Seoul, Korea) and Enzygnost anti-HIV1/2 Plus(Behringwerke, Marburg, Germany). The simultaneous detection of p24 antigenemia and anti-HIV1/2 antibodies was done with VIDAS DUO kit(bioMerieux, Lyon, France). The Vironostika HIV-1 antigen kit was used for detection of p24 antigen. The HIV RNA PCR and anti-HIV western blot assay were also performed to confirm the test results in discrepant cases. RESULTS: The simultaneous detection kit showed 100% sensitivity and 99.6% specificity. The possibility of earlier diagnosis than conventional anti-HIV1/2 EIA was also suggested by the results obtained with a group of consecutive panel sera infected with HIV. CONCLUSION: The simultaneous p24 antigen and anti-HIV1/2 detectin kit can be applied as a clinical screening test as a substitution of conventional anti-HIV1/2 EIA, and there is a probable gain especially in early diagnosis.